Hafnia alvei HA4597

Overview

Hafnia alvei is the first precision probiotic developed based on a target-based approach and a screening for strains producing ClpB, a protein mimicking alpha-MSH and activating the signals of satiety. Its mechanism of action and demonstration in efficacy in mice and humans make it a uniquely positioned, innovative next-gen probiotic for weight management.

Scientific reference(s)

https://www.mdpi.com/2072-6643/13/6/1902

https://pubmed.ncbi.nlm.nih.gov/27616451/

https://pubmed.ncbi.nlm.nih.gov/31911661/

https://pubmed.ncbi.nlm.nih.gov/31878078/

Additional info

Therapeutical area(s)

Cardiometabolic · Gut brain Axis · Weight management

Functionality

Satiety

Age/Gender

Adults · Women

Search strain on Pubmed

Hafnia alvei HA4597 is available at

TargEDys

Probiotics, LBPs, prebiotics & postbiotics + Go-to-market

MicrobiomeHUB is a space that brings together the companies of the microbiome industry

Brought to you by Clorofilla Scientific Publishing

This communication is only intended for business-to-business and health care professionals.
This communication is not intended for consumers of final consumer goods.
Nothing on this page is meant to be perceived as an approved claim.

Via Podgora 12/A, 20122, Milan, Italy – VAT: IT05299040963

Read MicrobiomeHUB’s Privacy Policy